Aurora B / FGFR / VEGFR (multi-kinase)

Class

Multi-targeted receptor tyrosine kinase inhibitor (oral)

Pathway

Combined anti-angiogenic (VEGFR/FGFR) and mitotic (Aurora B) kinase inhibition

This mechanism describes a single small molecule designed to inhibit three distinct kinases simultaneously: Aurora B, a serine/threonine kinase that governs chromosome segregation and cell division, and two receptor tyrosine kinases, FGFR (fibroblast growth factor receptor) and VEGFR (vascular endothelial growth factor receptor), which drive blood vessel formation and cell proliferation. Combining these activities in one agent targets cancer through two complementary routes: direct disruption of tumor cell division (via Aurora B) and starvation of the tumor's blood supply along with suppression of growth signaling (via VEGFR/FGFR). This dual approach is particularly relevant because tumors sometimes escape anti-angiogenic therapy by upregulating FGFR signaling as an alternative route to sustain vessel growth; inhibiting both receptor families at once may reduce that escape route. Diseases where this combined mechanism is broadly relevant include solid tumors with high vascular dependence and those harboring FGFR pathway alterations, where uncontrolled proliferation and neovascularization both contribute to progression. Because the drug acts on multiple kinases rather than one, its biological effects are broader than a selective inhibitor, offering potential efficacy advantages but also raising the likelihood of overlapping toxicities across the pathways it engages.